These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 19638958)

  • 1. Self-inactivating retroviral vector-mediated gene transfer induces oncogene activation and immortalization of primary murine bone marrow cells.
    Bosticardo M; Ghosh A; Du Y; Jenkins NA; Copeland NG; Candotti F
    Mol Ther; 2009 Nov; 17(11):1910-8. PubMed ID: 19638958
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The long terminal repeat negative control region is a critical element for insertional oncogenesis after gene transfer into hematopoietic progenitors with Moloney murine leukemia viral vectors.
    Ikawa Y; Uchiyama T; Jagadeesh GJ; Candotti F
    Gene Ther; 2016 Nov; 23(11):815-818. PubMed ID: 27487944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cell-culture assays reveal the importance of retroviral vector design for insertional genotoxicity.
    Modlich U; Bohne J; Schmidt M; von Kalle C; Knöss S; Schambach A; Baum C
    Blood; 2006 Oct; 108(8):2545-53. PubMed ID: 16825499
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Deletion of the LTR enhancer/promoter has no impact on the integration profile of MLV vectors in human hematopoietic progenitors.
    Moiani A; Miccio A; Rizzi E; Severgnini M; Pellin D; Suerth JD; Baum C; De Bellis G; Mavilio F
    PLoS One; 2013; 8(1):e55721. PubMed ID: 23383272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A self-inactivating gamma-retroviral vector reduces manifestations of mucopolysaccharidosis I in mice.
    Metcalf JA; Ma X; Linders B; Wu S; Schambach A; Ohlemiller KK; Kovacs A; Bigg M; He L; Tollefsen DM; Ponder KP
    Mol Ther; 2010 Feb; 18(2):334-42. PubMed ID: 19844196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Transcriptional enhancers induce insertional gene deregulation independently from the vector type and design.
    Maruggi G; Porcellini S; Facchini G; Perna SK; Cattoglio C; Sartori D; Ambrosi A; Schambach A; Baum C; Bonini C; Bovolenta C; Mavilio F; Recchia A
    Mol Ther; 2009 May; 17(5):851-6. PubMed ID: 19293778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced genotoxicity of avian sarcoma leukosis virus vectors in rhesus long-term repopulating cells compared to standard murine retrovirus vectors.
    Hu J; Renaud G; Gomes TJ; Ferris A; Hendrie PC; Donahue RE; Hughes SH; Wolfsberg TG; Russell DW; Dunbar CE
    Mol Ther; 2008 Sep; 16(9):1617-23. PubMed ID: 18578011
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A murine leukemia virus (MuLV) long terminal repeat derived from rhesus macaques in the context of a lentivirus vector and MuLV gag sequence results in high-level gene expression in human T lymphocytes.
    Kung SK; An DS; Chen IS
    J Virol; 2000 Apr; 74(8):3668-81. PubMed ID: 10729143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tissue-specific gene expression from Mo-MLV retroviral vectors with hybrid LTRs containing the murine tyrosinase enhancer/promoter.
    Vile RG; Diaz RM; Miller N; Mitchell S; Tuszyanski A; Russell SJ
    Virology; 1995 Dec; 214(1):307-13. PubMed ID: 8525635
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Self-inactivating MLV vectors have a reduced genotoxic profile in human epidermal keratinocytes.
    Cavazza A; Cocchiarella F; Bartholomae C; Schmidt M; Pincelli C; Larcher F; Mavilio F
    Gene Ther; 2013 Sep; 20(9):949-57. PubMed ID: 23615186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of residual promoter activity in γ-retroviral self-inactivating (SIN) vectors.
    Xu W; Russ JL; Eiden MV
    Mol Ther; 2012 Jan; 20(1):84-90. PubMed ID: 22008914
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retroviral vectors for the transduction of autoregulated, bidirectional expression cassettes.
    Unsinger J; Kröger A; Hauser H; Wirth D
    Mol Ther; 2001 Nov; 4(5):484-9. PubMed ID: 11708885
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Reducing the genotoxic potential of retroviral vectors.
    Ramezani A; Hawley TS; Hawley RG
    Methods Mol Biol; 2008; 434():183-203. PubMed ID: 18470646
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Leukemia induction after a single retroviral vector insertion in Evi1 or Prdm16.
    Modlich U; Schambach A; Brugman MH; Wicke DC; Knoess S; Li Z; Maetzig T; Rudolph C; Schlegelberger B; Baum C
    Leukemia; 2008 Aug; 22(8):1519-28. PubMed ID: 18496560
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Foamy Virus Vector Carries a Strong Insulator in Its Long Terminal Repeat Which Reduces Its Genotoxic Potential.
    Goodman MA; Arumugam P; Pillis DM; Loberg A; Nasimuzzaman M; Lynn D; van der Loo JCM; Dexheimer PJ; Keddache M; Bauer TR; Hickstein DD; Russell DW; Malik P
    J Virol; 2018 Jan; 92(1):. PubMed ID: 29046446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enhancers are major targets for murine leukemia virus vector integration.
    De Ravin SS; Su L; Theobald N; Choi U; Macpherson JL; Poidinger M; Symonds G; Pond SM; Ferris AL; Hughes SH; Malech HL; Wu X
    J Virol; 2014 Apr; 88(8):4504-13. PubMed ID: 24501411
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Retroviral vectors for high-level transgene expression in T lymphocytes.
    Engels B; Cam H; Schüler T; Indraccolo S; Gladow M; Baum C; Blankenstein T; Uckert W
    Hum Gene Ther; 2003 Aug; 14(12):1155-68. PubMed ID: 12908967
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple modifications allow high-titer production of retroviral vectors carrying heterologous regulatory elements.
    Hlavaty J; Stracke A; Klein D; Salmons B; Günzburg WH; Renner M
    J Virol; 2004 Feb; 78(3):1384-92. PubMed ID: 14722293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Promoter choice for retroviral vectors: transcriptional strength versus trans-activation potential.
    Weber EL; Cannon PM
    Hum Gene Ther; 2007 Sep; 18(9):849-60. PubMed ID: 17767401
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Physiological promoters reduce the genotoxic risk of integrating gene vectors.
    Zychlinski D; Schambach A; Modlich U; Maetzig T; Meyer J; Grassman E; Mishra A; Baum C
    Mol Ther; 2008 Apr; 16(4):718-25. PubMed ID: 18334985
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.